Drugs / DC activated CIK
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01235845 | Jan 2011 → Dec 2012 | malignant glioma | Qingdao University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC activated CIK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01235845 ↗ |
| Known as | DCIK | “CIK cells activated by DCs stimulation (DCIKs)have a characteristic which cytotoxic activity enhanced and show increased anti-tumor activity.” NCT01235845 ↗ |
| Modality | Cell therapy | “Cytokine-induced killer (CIK)cells are shown to be a heterogeneous population” NCT01235845 ↗ |
| Route | Other | “DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir” NCT01235845 ↗ |